Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

In addition to the presentations, Medicenna’s management team will be available for one-on-one meetings with investors at both conferences. Investors interested in scheduling a meeting can contact ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...